You are here
Home > 2020 > April > 01

iTeos Therapeutics Closes $125 Million Series B2 Financing

iTeos Therapeutics Closes $125 Million Series B2 Financing
 
– Proceeds support advancing clinical development of next-generation cancer immunotherapies targeting A2A adenosine receptor and anti-TIGIT immune checkpoint –

– Oversubscribed round co-led by new investors RA Capital Management and Boxer

Radient Technologies Inc. Applies to Extend Warrants

EDMONTON, Alberta, March 31, 2020 (GLOBE NEWSWIRE) — Radient Technologies Inc. (“Radient” or the “Company”) (TSX Venture: RTI; OTCQX: RDDTF), a global commercial manufacturer of high quality cannabinoid-based ingredients, formulations and products, has applied to the TSX Venture …

Top